Thomas Tredennick is Director of Technical Operations at Moonlight Bio, a clinical-stage biotech developing next-generation T cell therapies for cancer, where he oversees supply chain, vein-to-vein logistics, CDMO management, and CMC regulatory submissions for Phase I/II autologous cell therapy programs. He brings over 15 years of biopharma operations experience, including roles at ArsenalBio and Kite Pharma, where he contributed to FDA and EMA-approved CAR-T therapy, as well as earlier positions at Vetter Pharma and Baxter BioScience. Thomas holds a Master of Bioscience from Keck Graduate Institute, a B.S. in Biological Engineering from Cornell University.